Biologic response modifiers in the management of superficial bladder cancer.
For the treatment of existing transitional-cell carcinoma or for prophylaxis of recurrent disease, intravesical therapy should be chosen according to stage. Papillary disease (stages Ta, Tl) may be treated effectively either with an alkylating agent or with bacillus Calmette-Guérin (BCG). BCG is the agent of choice for the treatment of Hat carcinoma in situ (Tis), with the recommended treatment course comprising 12 weekly and 12 monthly instillations. Intravesical interferon and many of the other biologic response modifiers mentioned herein may be effective for patients with Ta disease who have failed BCG therapy.
Serels
S
S
Jack D. Weiler Hospital, Bronx, NY 10461, USA.
Fleischmann
J
J
D000283:Administration, Intravesical; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007167:Immunotherapy; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D007155:Immunologic Factors